# A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome

> **NCT03651726** · PHASE2 · UNKNOWN · sponsor: **Neurothera Labs Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** THX-110 (dronabinol plus PEA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03651726
- **Lead sponsor:** Neurothera Labs Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03651726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03651726, "A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT03651726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*